Notably, the results of a double-blind, randomized clinical trial conducted in a group of patients diagnosed with dyslipidemia showed that the administration of 450 mg naringin daily for 3 months significantly decreased BMI, total cholesterol, and LDL-cholesterol and, in addition, induced a significant increase in adiponectin levels (0.82 ± 0.25 μg/mL in the naringin-treated group vs. 0.59 ± 0.19 μg/mL in the placebo group), indicating the anti-obesity effects of naringin [104]. The gene discussed is ADIPOQ; the disease is obesity due to melanocortin 4 receptor deficiency.